AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10548325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both AFFQs compared with diet records
Number of subjects: 139
Study 7751430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg and Hydrochlorothiazide 6.25 mg (B5/H6.25)
Number of subjects: 0
Study 7751430 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol 5 mg (B5)
Number of subjects: 0
Study 7751430 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg (H25)
Number of subjects: 0
Study 2340838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet-controlled release (CR4) 50 mg carbidopa/200 mg levodopa
Number of subjects: 24
Study 2340838 — intervention group
Group type: COMPARATOR
Intervention: Sinemet 25/100
Number of subjects: 24
Study 881095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol hydrochloride
Number of subjects: 38
Study 881095 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 38
Study 30565745 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and lactoferrin (2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days, then 1 capsule/day for 10 consecutive days each month for 6 months)
Number of subjects: 48
Study 30565745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days, then 1 capsule/day for 10 consecutive days each month for 6 months)
Number of subjects: 48
Study 29202767 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 12.5 μg BID
Number of subjects: 378
Study 29202767 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 25 μg BID
Number of subjects: 378
Study 29202767 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 50 μg BID
Number of subjects: 378
Study 29202767 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg BID
Number of subjects: 378
Study 26338699 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (300 min/week) aerobic exercise
Number of subjects: 400
Study 26338699 — intervention group
Group type: COMPARATOR
Intervention: MODERATE (150 min/week) aerobic exercise
Number of subjects: 400
Study 23553637 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (QTP)
Number of subjects: 222
Study 23553637 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 222
Study 23553637 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (RIS)
Number of subjects: 222
Study 23553637 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole (ARP)
Number of subjects: 222
Study 23553637 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) in female participants
Number of subjects: 222
Study 23553637 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) in male participants
Number of subjects: 222
Study 16953529 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg intravenous morphine
Number of subjects: 160
Study 16953529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 15364136 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with cisplatin and vinorelbine; cisplatin 80 mg/m² on day 1, vinorelbine 25 mg/m² on days 1 and 4 of cycles 1 and 4, and 12.5 mg/m² during cycles 2 and 3; RT started on day 4 of cycle 2.
Number of subjects: 102
Study 15364136 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy (CRT) with cisplatin and vinorelbine; same chemotherapy regimen as concurrent arm; RT started within 2 weeks after completion of chemotherapy.
Number of subjects: 102
Study 15364136 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent CRT
Number of subjects: 102
Study 15364136 — intervention group
Group type: COMPARATOR
Intervention: Sequential CRT
Number of subjects: 102
Study 10714910 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised 17beta oestradiol (2 mg daily) + dydrogesterone (5-20 mg for last 14 days)
Number of subjects: 271
Study 9013370 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 24
Study 9013370 — intervention group
Group type: COMPARATOR
Intervention: Control (nonusers)
Number of subjects: 24
Study 1731540 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mL of 5% dextrose + 1000 mL of Ringers solution (RS) + 250 mL of 5% human albumin (HA)
Number of subjects: 60
Study 1731540 — intervention group
Group type: EXPERIMENTAL
Intervention: 1750 mL of RS + 500 mL of 3.5% gelatin
Number of subjects: 60
Study 1731540 — intervention group
Group type: EXPERIMENTAL
Intervention: 1850 mL of RS + 400 mL of 20% HA
Number of subjects: 60
Study 1731540 — intervention group
Group type: EXPERIMENTAL
Intervention: 1750 mL of RS + 500 mL of 10% low molecular weight hydroxyethyl starch
Number of subjects: 60
Study 1731540 — intervention group
Group type: EXPERIMENTAL
Intervention: 2250 mL of RS
Number of subjects: 60
Study 1731540 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 60
Study 3891584 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple tetracycline or erythromycin stearate (two week course)
Number of subjects: 113
Study 3891584 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 113
Study 31747825 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injections combined with upper-limb physiotherapy
Number of subjects: 28
Study 31747825 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections combined with upper-limb physiotherapy
Number of subjects: 28
Study 30626439 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone counselling intervention (3 phone calls focused on stress reduction and self-management strategies)
Number of subjects: 359
Study 27888473 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol acetate
Number of subjects: 32
Study 27888473 — intervention group
Group type: COMPARATOR
Intervention: Gomenol oil
Number of subjects: 32
Study 26099918 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis (DO)
Number of subjects: 66
Study 26099918 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Sagittal Split Osteotomy (BSSO)
Number of subjects: 66
Study 24780350 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D titanium miniplate and screws
Number of subjects: 30
Study 24780350 — intervention group
Group type: COMPARATOR
Intervention: Standard titanium miniplates and screws
Number of subjects: 30
Study 22465175 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretics (N = 192)
Number of subjects: 3069
Study 22465175 — intervention group
Group type: COMPARATOR
Intervention: ACE‐I or AT2RB
Number of subjects: 3069
Study 19307987 — intervention group
Group type: COMPARATOR
Intervention: Medication-only condition
Number of subjects: 254
Study 19307987 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication and behavioral treatment
Number of subjects: 254
Study 19307987 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological adherence measures via saliva assays
Number of subjects: 254
Study 19307987 — intervention group
Group type: COMPARATOR
Intervention: Parent report of medication adherence
Number of subjects: 254
Study 17710011 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose remifentanil (0.4 microg/kg/min)
Number of subjects: 42
Study 17710011 — intervention group
Group type: COMPARATOR
Intervention: Low dose remifentanil (0.1 microg/kg/min)
Number of subjects: 42
Study 15140851 — intervention group
Group type: EXPERIMENTAL
Intervention: OA Knee programme
Number of subjects: 40
Study 15140851 — intervention group
Group type: EXPERIMENTAL
Intervention: OA Hip programme
Number of subjects: 40
Study 15140851 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 11558855 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 11558855 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0
Study 11558855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0
Study 11558855 — intervention group
Group type: COMPARATOR
Intervention: GP IIb/IIIa-receptor inhibitors
Number of subjects: 0
Study 11558855 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban and Abciximab
Number of subjects: 0
Study 9678793 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell factor (SCF) 20 microg/kg plus G‐CSF
Number of subjects: 0
Study 9678793 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF alone
Number of subjects: 0
Study 9678793 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF 20 microg/kg plus G‐CSF 5 microg/kg
Number of subjects: 0
Study 9678793 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF administration
Number of subjects: 0
Study 8205878 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV with 2.5 mg albuterol (internal percussive component activated)
Number of subjects: 9
Study 8205878 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV with 2.5 mg albuterol (internal percussive component inactivated) followed by P&PD
Number of subjects: 9
Study 8205878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer with 2.5 mg albuterol followed by P&PD
Number of subjects: 9
Study 8205878 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV
Number of subjects: 9
Study 8205878 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 9
Study 2913847 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic transdermal scopolamine patches
Number of subjects: 32
Study 2913847 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 32
Study 30698839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (16 mg)
Number of subjects: 96
Study 30698839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 28704377 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Coaching Concept (TCC)
Number of subjects: 305
Study 28704377 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 305
Study 25498847 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying with dichlorodiphenyltrichloroethane plus LLINs
Number of subjects: 7845
Study 25498847 — intervention group
Group type: COMPARATOR
Intervention: LLINs alone
Number of subjects: 7845
Study 22302453 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal treatment during pregnancy
Number of subjects: 303
Study 22302453 — intervention group
Group type: COMPARATOR
Intervention: Control group (one session of supragingival scaling and oral hygiene instruction after delivery)
Number of subjects: 303
Study 21777233 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole plus antiepileptics
Number of subjects: 123
Study 21777233 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptics only
Number of subjects: 123
Study 19343018 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet group (n = 34)
Number of subjects: 65
Study 19343018 — intervention group
Group type: COMPARATOR
Intervention: Control group (information only, n = 31)
Number of subjects: 65
Study 19343018 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet group (compliers)
Number of subjects: 65
Study 19343018 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet group (noncompliers)
Number of subjects: 65
Study 19343018 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 16946304 — intervention group
Group type: EXPERIMENTAL
Intervention: R-maintenance after R-FCM
Number of subjects: 176
Study 16946304 — intervention group
Group type: COMPARATOR
Intervention: R-FCM
Number of subjects: 176
Study 16946304 — intervention group
Group type: EXPERIMENTAL
Intervention: R-maintenance after R-FCM in FL
Number of subjects: 176
Study 16946304 — intervention group
Group type: EXPERIMENTAL
Intervention: R-maintenance after R-FCM in MCL
Number of subjects: 176
Study 15651177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0
Study 15651177 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (echinocandin)
Number of subjects: 0
Study 15651177 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0
Study 15651177 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid formulation of amphotericin B or echinocandin
Number of subjects: 0
Study 11294164 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry participants
Number of subjects: 229
Study 11294164 — intervention group
Group type: EXPERIMENTAL
Intervention: Grateful participants
Number of subjects: 229
Study 11294164 — intervention group
Group type: COMPARATOR
Intervention: Sad participants
Number of subjects: 229
Study 11294164 — intervention group
Group type: COMPARATOR
Intervention: Happy participants
Number of subjects: 229
Study 9431533 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream
Number of subjects: 196
Study 9431533 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 196
Study 8290742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 31
Study 8290742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31013539 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Premature Infant Oral Motor Intervention (PIOMI), given 15 to 30 minutes before feeding once a day for 14 days
Number of subjects: 151
Study 31013539 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 151
Study 31013539 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Premature Infant Oral Motor Intervention (PIOMI)
Number of subjects: 151
Study 28712955 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing right ventricular stroke work index (RVSWI)
Number of subjects: 175
Study 28712955 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing left ventricular stroke work index (LVSWI)
Number of subjects: 175
Study 28712955 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔRVSWI ≤1.07 mm Hg⋅L⋅m-2 and ΔLVSWI ≤4.57 mm Hg⋅L⋅m-2
Number of subjects: 175
Study 26033416 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral oestrogen
Number of subjects: 915
Study 26033416 — intervention group
Group type: COMPARATOR
Intervention: Total androgen blockade
Number of subjects: 915
Study 26033416 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC-C30 ratings
Number of subjects: 915
Study 25528363 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF-23 levels above the median (395 RU/mL)
Number of subjects: 600
Study 25528363 — intervention group
Group type: COMPARATOR
Intervention: FGF-23 levels below the median
Number of subjects: 600
Study 22459731 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 15
Study 22459731 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 15
Study 20547698 — intervention group
Group type: EXPERIMENTAL
Intervention: Online questionnaire
Number of subjects: 1329
Study 20547698 — intervention group
Group type: COMPARATOR
Intervention: Postal questionnaire
Number of subjects: 1329
Study 18727823 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback pamphlet condition
Number of subjects: 0
Study 18727823 — intervention group
Group type: COMPARATOR
Intervention: Control pamphlet condition
Number of subjects: 0
Study 18727823 — intervention group
Group type: COMPARATOR
Intervention: No intervention control condition
Number of subjects: 0
Study 15836716 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d., amoxicillin 1 g b.d., and clarithromycin 500 mg b.d. (RAC group, n = 28)
Number of subjects: 116
Study 15836716 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d., metronidazole 500 mg b.d., and tetracycline 500 mg b.d. (RMT group, n = 28)
Number of subjects: 116
Study 15836716 — intervention group
Group type: COMPARATOR
Intervention: First-line Maastricht therapy
Number of subjects: 116
Study 15836716 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC group
Number of subjects: 116
Study 15836716 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT group
Number of subjects: 116
Study 12053583 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated T cells
Number of subjects: 0
Study 12053583 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stimulated T cell cultures with added monocytes
Number of subjects: 0
Study 12053583 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated T lymphocytes with added monocytes
Number of subjects: 0
Study 12053583 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-atopic asthma patients)
Number of subjects: 0
Study 10986030 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologous platelet lysate applied twice per week for up to 9 months in combination with standardised compression bandaging
Number of subjects: 86
Study 10986030 — intervention group
Group type: COMPARATOR
Intervention: Placebo buffer solution applied twice per week for up to 9 months in combination with standardised compression bandaging
Number of subjects: 86
Study 8674804 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine
Number of subjects: 339
Study 8674804 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine
Number of subjects: 339
Study 8674804 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 339
Study 1944755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin and low-dose prednisone
Number of subjects: 28
Study 1944755 — intervention group
Group type: COMPARATOR
Intervention: High-dose prednisone
Number of subjects: 28
Study 6864445 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (exposed to two treatments designed to reduce imitation of aggressive behaviors)
Number of subjects: 169
Study 6864445 — intervention group
Group type: COMPARATOR
Intervention: Control group (received comparable neutral treatments)
Number of subjects: 169
Study 6864445 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 169
Study 31419080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) 1 g
Number of subjects: 100
Study 31419080 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 29196478 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 160
Study 29196478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hypnotherapy (HT)
Number of subjects: 160
Study 25274048 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive risk-based strategy
Number of subjects: 1483
Study 25274048 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 1483
Study 23835709 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) - take-home booklet
Number of subjects: 276
Study 23835709 — intervention group
Group type: COMPARATOR
Intervention: Standard information booklet (control condition)
Number of subjects: 276
Study 22131203 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr, di‐creatine citrate; n=27)
Number of subjects: 55
Study 22131203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL; n=28)
Number of subjects: 55
Study 19318634 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor D (50 microg selenium, 30 mg vitamin E, and 15 mg beta-carotene)
Number of subjects: 29584
Study 19318634 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor D
Number of subjects: 29584
Study 16980004 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 80
Study 16980004 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 80
Study 11995457 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 preoperative immunotherapy (12 million IU/day subcutaneously for 3 consecutive days prior to surgery)
Number of subjects: 30
Study 11995457 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 preoperative immunotherapy
Number of subjects: 30
Study 11995457 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 30
Study 10431942 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of caffeine
Number of subjects: 62
Study 10431942 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of caffeine
Number of subjects: 62
Study 10431942 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of caffeine (placebo)
Number of subjects: 62
Study 8549887 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge (DBPCFC)
Number of subjects: 17
Study 8549887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8549887 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet history
Number of subjects: 17
Study 8549887 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire assessment
Number of subjects: 17
Study 8549887 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually based diet after 3-4 months
Number of subjects: 17
Study 2124540 — intervention group
Group type: EXPERIMENTAL
Intervention: Protriptyline
Number of subjects: 18
Study 582360 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 115
Study 582360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 6628517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 8
Study 30777122 — intervention group
Group type: EXPERIMENTAL
Intervention: Consult for Addiction Treatment and Care in Hospitals (CATCH) model
Number of subjects: 0
Study 30777122 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 28719977 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, motion capture rehabilitation
Number of subjects: 73
Study 28719977 — intervention group
Group type: COMPARATOR
Intervention: Usual care stroke rehabilitation
Number of subjects: 73
Study 25343955 — intervention group
Group type: EXPERIMENTAL
Intervention: Aryoseven (90 to 120 μg/kg intravenously every 2 hours)
Number of subjects: 66
Study 25343955 — intervention group
Group type: COMPARATOR
Intervention: Novoseven (90 to 120 μg/kg intravenously every 2 hours)
Number of subjects: 66
Study 25343955 — intervention group
Group type: EXPERIMENTAL
Intervention: Aryoseven
Number of subjects: 66
Study 25343955 — intervention group
Group type: COMPARATOR
Intervention: Novoseven
Number of subjects: 66
Study 24509688 — intervention group
Group type: EXPERIMENTAL
Intervention: His or para-His pacing (HP)
Number of subjects: 38